South Africa

Pfizer begins study of oral drug for prevention of Covid-19

To date, Gilead Sciences Inc's intravenous drug remdesivir is the only approved antiviral treatment for Covid-19 in the US.

Pfizer has also started another study of PF-07321332 in non-hospitalised, symptomatic adult patients.

Merck and partner Ridgeback Biotherapeutics recently launched a late-stage trial of their experimental drug molnupiravir for prevention of the Covid-19 infection.

Molnupiravir is also being studied in a late-stage trial in non-hospitalised patients to see if it reduces the risk of hospitalisation or death.

Reuters

Pfizer Inc said on Monday it has started a large study testing its investigational oral antiviral drug for the prevention of Covid-19 infection among those who have been exposed to the virus.

The drugmaker and its rivals, including US-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG , have been racing to develop an easy-to-administer antiviral pill for Covid-19.

The mid-to-late-stage study will test Pfizer's drug, PF-07321332, in up to 2,660 healthy adult participants aged 18 and older who live in the same household as an individual with a confirmed symptomatic Covid-19 infection.

In the trial, PF-07321332, designed to block the activity of a key enzyme needed for the coronavirus to multiply, will be administered along with a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection.

Football news:

Dani Alves: If Barcelona thinks they need me, it's a matter of one call. I can still be useful
Lewandowski wants to move to Real Madrid. He will ask Bayern for a transfer (As)
Sarri about the calendar: Football is no longer a sport, but a show from which they are trying to squeeze as much money as possible
Calvert-Lewin is Arsenal's main target for the summer. Lacazette and Nketiah will leave for free
Tuchel about Newcastle: A new contender for the title. The Premier League is the most difficult league in the world, and it is getting more and more difficult
The director of Barca about Dembele and Roberto: They want to stay, but the club has to adjust salaries. This complicates the negotiations
Benzema on the Golden Ball: I have done a lot in the last 3-4 years and I continue to play at a high level